Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials.

@article{Holland2016LifitegrastCE,
  title={Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials.},
  author={Edward J. Holland and Walter O Whitley and Kenneth N. Sall and Stephen S. Lane and Aparna Raychaudhuri and Steven E. Sibley Yuhang Xing Xiaoyan Zhang and Amir Shojaei},
  journal={Current medical research and opinion},
  year={2016},
  pages={1-7}
}
OBJECTIVE Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED). RESEARCH DESIGN AND METHODS Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed. MAIN OUTCOME MEASURES Phase 2, pre… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
3 Citations
0 References
Similar Papers

Similar Papers

Loading similar papers…